Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR-145

International Journal of Oncology

Volumn 42, Issue 4, 2013, Pages 1473-1481

  Ren, Dong ^a   Wang, Min ^a   Guo, Wei ^a   Zhao, Xiaohui ^b   Tu, Xiang'an ^a   Huang, Shuai ^a   Zou, Xuenong ^a   Peng, Xinsheng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Cancer cell stemness; Epithelial mesenchymal transition; MicroRNAs; Prostate cancer; Wild type p53

Indexed keywords

FIBRONECTIN; HERMES ANTIGEN; KRUPPEL LIKE FACTOR 4; MICRORNA 145; MYC PROTEIN; NERVE CELL ADHESION MOLECULE; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN P53; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CANCER STEM CELL; CELL ADHESION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; UPREGULATION;

ANTIGENS, DIFFERENTIATION; CELL ADHESION; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; SPHEROIDS, CELLULAR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874609641     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1825     Document Type: Article

References (45)

1. Carlin BI and Andriole GL: The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88:2989-2994, 2008.
2. Vousden KH and Prives C: Blinded by the light: the growing complexity of p53. Cell 137:413-431, 2009.
3. Goh AM, Coffill CR and Lane DP: The role of mutant p53 in human cancer. J Pathol 223:116-126, 2011.
4. Muller PA, Vousden KH and Norman JC: p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192:209-218, 2011.
5. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, Von Eschenbach AC and Logothetis CJ: p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 161:304-308, 1999.
6. Wang SP, Wang WL, Chang YL, et al: p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol 11:694-704, 2009.
7. Boominathan L: The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network. Cancer Metastasis Rev 29:613-639, 2010.
8. Chang CJ, Chao CH, Xia W, et al: p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 13:317-323, 2011.
9. Kim NH, Kim HS, Li XY, et al: A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol 195:417-433, 2011.
10. Kim T, Veronese A, Pichiorri F, et al: p53 regulates epithelial- mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 208:875-883, 2011.
11. Schubert J and Brabletz T: p53 spreads out further: suppression of EMT and stemness by activating miR-200c expression. Cell Res 21:705-707, 2011.
12. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144:646-674, 2011.
13. Sethi S, Macoska J, Chen W and Sarkar FH: Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res 3:90-99, 2010.
14. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED and Thompson EW: Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 213:374-383, 2007.
15. Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755-768, 2008.
16. Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science 331:1559-1564, 2011.
17. Monteiro J and Fodde R: Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur J Cancer 46:1198-1203, 2010.
18. Bracken CP, Gregory PA, Khew-Goodall Y and Goodall GJ: The role of microRNAs in metastasis and epithelial-mesenchymal transition. Cell Mol Life Sci 66:1682-1699, 2009.
19. Gregory PA, Bert AG, Paterson EL, et al: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10:593-601, 2008.
20. Korpal M, Lee ES, Hu G and Kang Y: The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283:14910-14914, 2008.
21. Liu C, Kelnar K, Liu B, et al: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17:211-215, 2011.
22. Siemens H, Jackstadt R, Hünten S, Kaller M, Menssen A, Götz U and Hermeking H: miR-34 and SNAIL form a doublenegative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 10:4256-4271, 2011.
23. Hatfield S and Ruohola-Baker H: microRNA and stem cell function. Cell Tissue Res 331:57-66, 2008.
24. Hermeking H: MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer 12:613-626, 2012.
25. Peng X, Guo W, Liu T, et al: Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One 6:e20341, 2011.
26. Huang S, Guo W, Tang Y, Ren D, Zou X and Peng X: miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. Oncol Rep 28:1831-1837, 2012.
27. Sachdeva M, Zhu S, Wu F, et al: p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 106:3207-3212, 2009.
28. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S and Miyazono K: Modulation of microRNA processing by p53. Nature 460:529-533, 2009.
29. Shi M, Du L, Liu D, et al: Glucocorticoid regulation of a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy resistance of cervical cancer cells. J Pathol 228:148-157, 2011.
30. Suh SO, Chen Y, Zaman MS, et al: MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis 32:772-778, 2011.
31. Schmittgen TD and Livak KJ: Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) method. Methods 25:402-408, 2011.
32. Pfeiffer MJ and Schalken JA: Stem cell characteristics in prostate cancer cell lines. Eur Urol 57:246-254, 2010.
33. Bisson I and Prowse DM: WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 19:683-697, 2009.
34. Xu N, Papagiannakopoulos T, Pan G, Thomson JA and Kosik KS: MicroRNA-145 regulates OCT-4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 137:647-658, 2009.
35. Downing S, Bumak C, Nixdorf S, Ow K, Russell P and Jackson P: Elevated levels of prostate-specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis. Mol Carcinog 38:130-140, 2003.
36. Stapleton AM, Timme TL, Gousse AE, et al: Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 3:1389-1397, 1997.
37. Kogan-Sakin I, Tabach Y, Buganim Y, et al: Mutant p53 (R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ 18:271-281, 2011.
38. Vinall RL, Chen JQ, Hubbard NE, Sulaimon SS, Shen MM, Devere White RW and Borowsky AD: Initiation of prostate cancer in mice by Tp53R270H: evidence for an alternative molecular progression. Dis Model Mech 5:914-920, 2012.
39. Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, Roy-Burman P and Nikitin AY: Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 66:7889-7898, 2006.
40. Zhou Z, Flesken-Nikitin A and Nikitin AY: Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts. Cancer Res 67:5683-5690, 2007.
41. Martin P, Liu YN, Pierce R, et al: Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. Am J Pathol 179:422-435, 2011.
42. Dong P, Karaayvaz M, Jia N, et al: Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene: Jul. 30, 2012 (Epub ahead of print). doi: 10.1038/onc.2012.334.
43. Gao P, Xing AY, Zhou GY, et al: The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene 32:491-501, 2013.
44. Mani SA, Guo W, Liao MJ, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715, 2008.
45. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S and Sarkar FH: Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 5:e12445, 2010.